Verquvo

Verquvo – Vericiguat Tablets for Heart Failure Management

Verquvo​ provides effective support for patients with chronic heart failure with reduced ejection fraction (HFrEF). This soluble guanylate cyclase (sGC) stimulator improves cardiovascular function, reduces hospitalizations, and enhances patients’ quality of life.

Doctors prescribe Verquvo for adults with symptomatic HFrEF who remain at risk of worsening heart failure despite standard therapy. Patients take Verquvo orally once daily with or without food. Its once-daily dosing supports adherence and integrates smoothly into daily routines. Healthcare providers monitor heart function, blood pressure, and renal function to ensure optimal outcomes.

Verquvo enhances the nitric oxide-sGC-cGMP pathway, leading to improved cardiac efficiency and reduced vascular resistance. Patients experience increased exercise tolerance, reduced fatigue, and improved ability to perform daily activities. The therapy complements standard heart failure treatments, including ACE inhibitors, beta-blockers, diuretics, and mineralocorticoid receptor antagonists. Patients report fewer hospital visits and improved overall well-being while using Verquvo.

Verquvo​

Clinical studies show Verquvo reduces the risk of cardiovascular death or heart failure hospitalization. Doctors value its unique mechanism, predictable effect, and compatibility with existing heart failure medications. Patients benefit from a once-daily oral therapy that provides consistent cardiovascular support and reinforces comprehensive heart failure management.

Verquvo comes in oral tablets with precise dosing options. Patients gain confidence from accurate administration and reliable pharmacokinetics. Its formulation emphasizes safety, efficacy, and patient convenience. Verquvo empowers patients to manage chronic heart failure proactively while supporting long-term cardiovascular health.

Product Specifications

Verquvo enables patients to manage chronic heart failure confidently. Its long-acting effect, cardiovascular support, and convenient oral form make it a cornerstone therapy in modern heart failure care.